Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma
Study sponsor: Aura Biosciences
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-04-22Actual
Enrollment · participants22Actual
Source updated2025-03-03Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.